NASMAC is a joint venture between NASAQ, the daughter company of Zahran Holding, and Macleods Pharmaceuticals. This partnership brings together local expertise and international reach. NASMAC is committed to transforming Saudi Arabia’s healthcare sector with innovative and high-quality solutions.
At NASMAC, we are addressing the growing challenge of non-communicable chronic diseases (NCDs). With a clear focus on diseases such as cancer, respiratory conditions, and chronic conditions like diabetes and cardiovascular diseases, we provide accessible, affordable, and effective treatments that are made to meet the needs of patients and healthcare institutions across Saudi Arabia.
NASMAC, a joint venture between NASAQ (the daughter company of Zahran Holding Group) and Macleods Pharmaceuticals, represents more than just a business venture. From its inception, NASMAC was built to be a giant. It did not enter the market as any other company would; it came with the experience, technical expertise, and financial strength of its two founding entities.
Together, Zahran’s local expertise through NASAQ and Macleods’ international reach created the perfect synergy. This collaboration was designed to leverage Macleods’ extensive experience in drug development and manufacturing to produce a wide range of pharmaceutical products locally, especially for non-communicable diseases.
